|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration显示文摘 | Wedge SR Ogilvie DJ Dukes M | 2002 | Cancer Res2002，62，16： | 1 |
| 2 | ZD6474-a novel inhibitor of VEGFRand EGFR tyrosine kinase activity 显示文摘 | RYAN A J WEDGE SR | 2005 | Br J Cancer2005，92，1： | 1 |
| 3 | Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular - targeting agent ZD6126 produces an enhanced anti - tumorre-sponse显示文摘 | Wedge SR Kendrew J Ogilvie D J | 2002 | Proc Am Assoc Cancer Res2002，43，： | 1 |
| 4 | Inhibiting vascular endothelial growth factor signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer显示文摘 | Goodlad RA Ryan AJ Wedge SR | 2006 | Carcinogenesis2006，27，： | 1 |
| 5 | AZD2171:A highly potent,orally bioavailable,vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer显示文摘 | Wedge SR Kendrew J Hennequin LF | | 0，，10： | 1 |
| 6 | 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNC treatment in cell lines of variable mismatch repair status and O~-alkylguanine-DNA alkyl- transferase activity 显示文摘 | Wedge SR Porteous JK Newlands ES | 1996 | Br J Cancer1996，74，7： | 1 |
| 7 | Pharmacological efficacy of ZD6474, aVEGF receptor tyrosine kinase inhibitor, in rat 显示文摘 | Wedge SR Ogilvie Dukes M | 2001 | ( Abstract)Proceedings of the 92” Annal Meeting of the Americian Association for Cancer Research New Orleans (LA)2001，42，31： | 1 |
| 8 | AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer显示文摘 | Wedge SR Kendrew J Hennequin LF | 2005 | Cancer Res2005，65，10： | 1 |
| 9 | Dynamic contrastenhanced MRI study of human xenografts treated with the VEGF signaling inhibitor ZD6474 显示文摘 | Wedge SR Checkley D Tessier JJ | 2001 | Proceedings of the 92” Annual Meeting of the American Association for Cancer Research New Orleans (LS)2001，42，58： | 1 |
| 10 | Temozolomide:a review of its discovery,chemical properties,pre-clinical development and clinical trials显示文摘 | Newlands es Stevens MF Wedge SR | 1997 | Cancer Treat Rev1997，23，： | 1 |
| 11 | Temozolomide:a review of its discovery,chemical properties,pre-clinical development and clinical trials显示文摘 | Stevens MFG Wedge SR | 1997 | Cancer Treat Rev1997，23，： | 1 |
| 12 | Temozolomide: areview of its discovery, chemical properties, pre-clinical developmentand clinical trials显示文摘 | Newlands ES Stevens MF Wedge SR | 1997 | Cancer Treat Rev1997，23，1： | 1 |
| 13 | ZD4190:An orally active inhibitor of vascular endothelial growth factor receptor signaling with broad-spectrum antitumor efficacy显示文摘 | Ogiulvie DJ Dukes M | 2000 | Cancer Res2000，60，3： | 1 |
| 14 | Outcome at forty five years after open reduction and innominate osteotomy for late presenting developmental dislocation of the hip 显示文摘 | Thomas SR Wedge JH Salter RB | 2007 | J'' Bone Joint Surg Am2007，89，11： | 1 |
| 15 | ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration显示文摘 | Wedge SR Ogilvie DJ Dukes M | 2002 | Cancer Res2002，62，16： | 1 |
| 16 | ZD6474 inhibits vascular endothelial growth factor signaling,angiogenesis,and tumor growth following oral administration显示文摘 | Wedge SR Ogilvie DJ Dukes M | | 0，，16： | 1 |
| 17 | AZD2127:A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer显示文摘 | Wedge SR Kendrew J Hennequin LF | 2005 | Cancer Res2005，65，： | 1 |
| 18 | ZD6474-novel inhibitor of VEGFR and EGFR tyrosine kinase activity显示文摘 | Ryan AJ Wedge SR | 2005 | Br J Cancer2005，92，1： | 1 |
| 19 | N-(2-Hydrox-ypropyl)methacrylamide copolymer targeted to the hepatocyte galactose-receptor:pharmacokinetics in DBA2 mice显示文摘 | Seymour LW Ulbrich K Wedge SR | 1991 | Br J Cancer1991，63，6： | 1 |
| 20 | ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity显示文摘 | Ryan AJ1 Wedge SR | 2005 | Br J Cancer2005，92，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员